01:30 AM EST, 11/06/2026 (MT Newswires) -- Theraclion (ALTHE.PA) secured the US Food and Drug Administration's De Novo marketing authorization for Sonovein, its therapeutic ultrasound platform. The non-invasive treatment method is indicated for the coagulation of blood vessels in patients with superficial vein reflux in the great saphenous vein segments, according to a Friday release. The approval is backed by the results of the Veinreset study, which met its primary endpoint with a 96.8% great saphenous vein occlusion rate at 12 months. The French medical technology company will initially roll out Sonovein through physician training, clinical onboarding and technical and service support.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.